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Background
Research has consistently shown that genetics plays a critical role in 
prostate cancer (CaP) development, but the identification of CaP genes 
has proven to be very difficult.  Hereditary prostate cancer is a complex 
disease involving numerous genes and variable phenotypic expression.  
This heterogeneity has led researchers to pursue genes associated with 
alternative phenotypes for CaP, such as tumor aggressiveness.  Several 
recent linkage studies have used clinical and pathological data to define 
CaP aggressiveness as a qualitative trait.  The International Consortium for 
Prostate Cancer Genetics (ICPCG) recently completed such an analysis 
using pooled data from 11 member institutions.  This analysis required all 
families be small to moderate in size in order to facilitate standard linkage 
analysis software. Hence, although the ICPCG analysis included data from 
the Utah prostate cancer pedigree resource, the Utah pedigrees were not 
analyzed in their complete form.  Specifically, pedigrees were divided and 
trimmed before analysis, which reduced the power of the analysis to detect 
predisposition loci.  Here we present the results of a genome-wide scan for 
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Prostate cancer cases were required to meet at least one of the following 
criteria in order to be classified as aggressive: 1) regional or distant stage; 
2) poorly differentiated or undifferentiated grade; or 3) death due to 
metastatic prostate cancer, confirmed by death certificate.  Any prostate 
cancer cases not meeting this criteria were classified as having unknown 
prostate aggressiveness status.  We identified 259 subjects with
aggressive prostate cancer (APC) in 57 extended and nuclear families.  All 
pedigrees consisted of between two and six generations, with a median of 
3 generations.  Table I summarizes the characteristics of the pedigrees 
analyzed.  















Genotyping was performed by the Center for Inherited Disease Research 
(CIDR) on a set of 401 STR markers with an average spacing of 9 cM
across the 22 autosomes and the X chromosome.  Parametric and non-
parametric multipoint linkage statistics were calculated using the MCLINK 
software package, which uses Markov Chain Monte Carlo simulation
methods to sample haplotype configurations and to calculate an estimate 
of the LOD statistic.
* connecting ancestors of cases, and spouse with up to four 
children were genotyped when necessary to infer genotypes
Table I:  Summary of 57 Utah pedigrees with 2 or more aggressive prostate cancer cases
Results—Parametric Analysis
No significant results were observed at the genome-wide level, but 
suggestive evidence for linkage was observed on chromosomes 9q 
(HLOD=2.04), 14q (HLOD=2.08), and 6p (HLOD=1.75); several pedigrees 
showed individual evidence for linkage at each locus (LOD > 0.58). 
Stratification analyses by the number of affected subjects (less than five, five 
or more) and the average age at diagnosis of affected subjects (less than 70 
years, 70 or more years) were also performed. The subset of pedigrees with 
earlier age at onset demonstrated suggestive linkage evidence on
chromosomes 3q (HLOD=1.79), 8q (HLOD=1.67) and 20q (HLOD=1.82). 
The late onset subset showed suggestive linkage on chromosome 6p
(HLOD=2.37) and the subset of pedigrees with fewer than 5 affected 
subjects showed suggestive linkage on chromosome 10p (HLOD=1.99). 
Figure 1: HLOD statistic for chromosomes 1-22 and X.  The solid line represents the 
dominant model, and the broken line represents the recessive model.
Figure 2: Genome-wide HLOD results for the subsets of pedigrees with less than 5 
affected members, 5 or more affected members, average age at diagnosis less than 70 
years, and average age at diagnosis equal to or greater than 70 years.  The solid line 
represents results of the dominant model and the broken line represents the recessive 
model in each frame.
Figure 3: Qualitative NPL statistic for chromosomes 1-22.  The solid line represents the 
NPL statistic, while the broken line shows the equivalent LOD value.
Results—Non-parametric Analysis
Figure 3 shows the qualitative NPL statistic for the 22 autosomes.  No 
significant linkage evidence was observed.  The highest NPL statistic 
observed across the entire genome was 2.33 at D1S255 (56 cM) on 
chromosome 1p, corresponding to a LOD = 1.45. 
Conclusion
Although this analysis did not identify any regions with significant linkage 
evidence at the genome-wide level, regions of interest were identified on 
chromosomes 9, 14, 6, and 1.  The result on chromosome 6 appears to 
support linkage evidence reported previously by the ICPCG as well as the 
University of Michigan and the ACTANE consortium.  Additionally, using 
pedigree subsets of the data resource identified regions of interest on 
chromosomes 3, 8, 10 and 20.  The chromosome 20 result supports previous 
findings reported by researchers at Mayo Clinic and the ICPCG.  We did not 
find sufficient evidence to support linkage regions previously reported for 
aggressive prostate cancer by the ICPCG for chromosome 11, by the 
University of Michigan for chromosome 15, or by Wake Forest University or 
Fred Hutchinson for Chromosome 22.  Further research is necessary to 
identify the gene or genes responsible for prostate cancer aggressiveness 
and surmount the overarching problem of PC heterogeneity. 
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